Inhibitory effects and mechanisms of the anti-covid-19 traditional Chinese prescription, Keguan-1, on acute lung injury.

ABSTRACT:

Ethnopharmacological relevance

Keguan-1, a new traditional Chinese medicine (TCM) prescription contained seven Chinese herbs, is developed to treat coronavirus disease 19 (COVID-19). The first internationally registered COVID-19 randomised clinical trial on integrated therapy demonstrated that Keguan-1 significantly reduced the incidence of ARDS and inhibited the severe progression of COVID-19.

Aim of the study

To investigate the protective mechanism of Keguan-1 on ARDS, a lipopolysaccharide (LPS)-induced acute lung injury (ALI) model was used to simulate the pathological state of ARDS in patients with COVID-19, focusing on its effect and mechanism on ALI.

Materials and methods

Mice were challenged with LPS (2 mg/kg) by intratracheal instillation (i.t.) and were orall

SUBMITTER: Bai Z 

PROVIDER: S-EPMC8590745 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature